Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. - Wikidata - awgldk - TriplyDB

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

http://www.wikidata.org/entity/Q33289120

about

A mitotic function for the high-mobility group protein HMG20b regulated by its interaction with the BRC repeats of the BRCA2 tumor suppressor Cytotoxic and targeted therapy for hereditary cancers Genetics and biology of pancreatic ductal adenocarcinoma Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers Detecting statistical interaction between somatic mutational events and germline variation from next-generation sequence data.Quantitative RT-PCR gene expression analysis of laser microdissected tissue samples BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development.Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.Evolutionary pathways in BRCA1-associated breast tumors.Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.Assessment of SLX4 Mutations in Hereditary Breast Cancers.Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression.BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome BRCA1 and BRCA2: different roles in a common pathway of genome protection.Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.BRCA2 and TP53 collaborate in tumorigenesis in zebrafish.Hereditary ovarian cancer: biology, response to chemotherapy and prognosis.The fate of BRCA1-related germline mutations in triple-negative breast tumors.Tumour suppressor mechanisms in the control of chromosome stability: insights from BRCA2.Haploinsufficiency in mouse models of DNA repair deficiency: modifiers of penetrance.Chromosome instability and carcinogenesis: insights from murine models of human pancreatic cancer associated with BRCA2 inactivation High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients.Malignant transformation and stromal invasion from normal or hyperplastic tissues: true or false?BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations.Accurate quantification of homologous recombination in zebrafish: brca2 deficiency as a paradigm.Sensitizing HR-proficient cancers to PARP inhibitors.BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.

P2860

Q24297103-5A128CAF-3F57-447E-B051-960DD139BE18 Q26739366-D83C8108-50C5-4162-B04B-1130194ABF5D Q26765438-11A73D47-B19D-4B13-B3A4-3F378E86BD6B Q28085364-3E167348-4D50-4E2D-AE12-CE13560C6710 Q28512158-1F582C80-8FE8-4AF3-8EC5-7077D6306376 Q28542563-BA029B17-C770-47AA-AC41-2924B1D535A0 Q30705769-88C6BBEB-6EB0-4A55-A58E-8233551AFF29 Q33455428-62467AB7-AD2F-4637-88C0-9CF5B0685348 Q33783896-95B4E41F-1277-40CD-834B-B9332426559E Q33892942-D677738D-8381-4495-BE6E-E44A2AE12DDC Q34110729-0BC170A1-624A-4E3D-ACE0-7B3A8D4F5E9F Q34277174-E0E04B34-3FBE-4A16-B90A-603B95C17A4C Q34412496-85D7376D-4059-44CA-B644-C6438F9C5B7D Q34806183-56B09C18-1ECC-4549-A1A8-F2381C128ADA Q35470405-3C37F737-BF06-4CA4-9F33-D261751EE78A Q35683569-B142C89A-F532-4D4B-843C-006CAC7D97E1 Q36493279-AF7DDB80-3C8A-4523-84CA-916DEEED6F94 Q36642880-22FC0519-817F-4033-B567-8DA180F50417 Q36838404-88818CEE-4919-4F12-8112-1A0A2BCB76FE Q37022075-F7C1D3B2-8B30-41DC-B0C2-4E5EFE19DA15 Q37149848-48EFD918-F947-4497-B03A-432477F289EC Q37172320-1C08D913-44B0-4BAC-B28C-DEF9F6C710FC Q37228744-545911BA-27B0-494C-9E08-60443D544628 Q37360179-57C867F5-75ED-4E69-B92A-5505BCC00695 Q37410472-573EF8B8-B0EB-4583-A81A-93AB2EA75629 Q37529633-75DCBB12-F888-40DC-8178-33C56718BE44 Q37585309-26A9014D-D3C0-413F-A03B-7A6484CD6A68 Q37596828-6013D18F-2EA1-4703-B58D-9F2025FFF824 Q37604845-3DF289B4-E7FC-4318-AD1D-6A9D97D5A956 Q37939634-74380AAC-85D2-44C6-8DFE-3DFB93B10A8A Q38165518-3FBF21E5-8E9A-4C02-815D-7E9CECAB1BD5 Q39029780-B8E5D339-08AB-445C-BFB8-6CE22602D828 Q42036661-85043A9D-DCD3-4A72-9DAA-98B4E843B959 Q42482668-0EBBB67A-8CF5-478D-BD18-5429F58A703C Q43898530-465F29B0-3BA8-4CE0-AD2E-8F8E26FBD714 Q46168959-E75F7166-CD6E-4806-83C6-234EAE18D295 Q46443385-C384EDE3-2F8F-4D73-B29B-3C758761EA79 Q47142663-727376C3-3E9F-486F-8BA7-EAB21B5CD44C Q50056096-1E1EFF3B-C3A2-4616-A5EC-74E3051BDD16 Q50108671-F26C547C-2B44-4D9A-BE43-5811303867FA

P2860

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

http://www.wikidata.org/entity/Q33289120

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

@ast

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

@en

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

@nl

type

label

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

@ast

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

@en

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

@nl

prefLabel

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

@ast

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

@en

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

@nl

P1433

Q33289120-4F82348E-811D-4C27-802C-106BC19864CC

P1476

Q33289120-F821BED5-A89E-45B9-8183-BF1A557A36D6

P2093

Q33289120-0AFE1EEF-E2B1-43E7-AEDB-860FFC22D2FF

Q33289120-360352F8-F151-40B0-B3A5-F438F0ACB88C

Q33289120-8275D60D-5389-4160-976D-9ECCDA4B8139

Q33289120-A0764FF5-66E1-4E53-A23C-749E9840B429

Q33289120-ABFB9536-CAF2-47B2-91C0-6FD78864FC97

Q33289120-BAACBE71-57C1-4A6A-9BAE-C24E6DC0A6C7

Q33289120-BDE9CFAE-DC56-4288-8E98-8248DD8144A2

Q33289120-D24F9A6D-E4AB-4038-97A7-6D237600F862

Q33289120-D2B11566-0B30-4A16-A126-DA9EC5692DAB

P2860

Q33289120-7CBA5C48-AA7E-4E1D-9027-5F005A8DC60E

Q33289120-E8314D8B-B0D8-4489-9AD9-1380F15C9A1B

Q33289120-F3AB872E-7D9E-4EA1-862D-0EC93A813233

P2888

Q33289120-4B7B754F-0271-4B86-9B77-3405824A6D45

P304

Q33289120-106CA020-144A-4C40-AA18-721DC6FDABCC

P31

Q33289120-CEE4DE60-A16B-4DD3-9521-4FC539174928

P356

Q33289120-4A872297-47B0-43D8-80B1-9ACC3C4A9F50

P433

Q33289120-B77A641A-7E0A-497F-B1A0-B80F11AD63DA

P478

Q33289120-750469D7-DADB-428B-8D2A-8F5D3ECA0684

P50

Q33289120-0D9C2F40-98EB-47C6-8AC2-62FBC365B4AE

Q33289120-6004B389-2105-44C1-B883-901CA6015D86

Q33289120-AB4F0FE9-260F-40AC-BF2B-21C6C944FE6A

P577

Q33289120-3076BD50-9934-4CC1-AB88-925755360A84

P6179

Q33289120-37E1D48D-B600-4D52-B476-F04483E6CA75

P698

Q33289120-D9C72BB8-8B4B-4CC2-955E-4D4FA6E1A9AA

P356

S10434-007-9372-1

P1433

Annals of Surgical Oncology

P1476

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

@en

P2093

Cindy J Yee

http://www.w3.org/2001/XMLSchema#string

Douglas A Levine

http://www.w3.org/2001/XMLSchema#string

Edi Brogi

http://www.w3.org/2001/XMLSchema#string

Jeff Boyd

http://www.w3.org/2001/XMLSchema#string

Mary L Gemignani

http://www.w3.org/2001/XMLSchema#string

Narciso Olvera

http://www.w3.org/2001/XMLSchema#string

Patrick I Borgen

http://www.w3.org/2001/XMLSchema#string

Tari A King

http://www.w3.org/2001/XMLSchema#string

Weiwei Li

http://www.w3.org/2001/XMLSchema#string

P2860

Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas

BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications

Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers.

P2888

s10434-007-9372-1

P304

2510-2518

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-007-9372-1

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1027632582

http://www.w3.org/2001/XMLSchema#string

P698

17597348

http://www.w3.org/2001/XMLSchema#string